Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biotech company AC Immune has entered a license and research agreement with Genentech for the development of anti-beta-amyloid antibodies for the treatment of Alzheimer's and other diseases.
Subscribe to our email newsletter
Immune believes the agreement will provide it with a solid financial basis beyond the next three years to develop other programs at full speed.
Beta-amyloid constitutes an important target for the disease modification of Alzheimer’s disease and AC Immune has developed conformation-specific antibodies against this protein generated by its SupraAntigen Technology.
Under the terms of this agreement, Genentech will make an upfront payment to AC Immune, with the potential for a total of over $300 million in payments. Upon commercialization of a product, Genentech will pay AC Immune royalties on net sales of the antibodies. Genentech will also provide funding for a multi-year collaborative research program and will cover all development and clinical costs of the lead antibody and subsequent antibody candidates.
The SupraAntigen Technology resulted in the development of an anti-beta-amyloid antibody program with a selected lead antibody, which has been shown to be highly active in animal disease models for Alzheimer’s disease.